This pharmaceutical company has strong export of raw materials and sales growth has exceeded 40%

Bulk drugs refer to the raw materials used in the production of various preparations.
They are the effective ingredients in the preparations.
They are various powders, crystals, extracts, etc.
, prepared by chemical synthesis, plant extraction, or biotechnology
.
Since 2017, China has become one of the world's major API producers and exporters
.
According to statistics, in 2020, there will be about 1,300 API companies above designated size that will be included in the statistics.
The total output of APIs will exceed 2 million tons, and the operating income will be nearly 400 billion yuan, accounting for 16% of the total pharmaceutical manufacturing industry
.
After years of development, APIs have become a long-term advantage for China's pharmaceutical industry to participate in international competition
.
It is worth mentioning that since the outbreak of the epidemic, the global pharmaceutical industry chain has been impacted, which has further enhanced the strategic position of China's API industry
.
At the same time, the export orders of many API companies in China have also begun to increase sharply, and the sales volume and sales revenue of APIs have increased significantly
.
Recently, there have been reports that Northeast Pharmaceutical Group Co.
, Ltd.
(hereinafter referred to as "Northeast Pharmaceutical") saw a significant increase in export orders for APIs in November, and both the sales volume and sales revenue of APIs achieved double growth
.
Among them, the market for three types of APIs such as vitamins, amino acids, and antibiotics performed strongly, with sales volume and sales revenue increasing by more than 40% month-on-month
.
It is worth mentioning that since October this year, nearly 10 API products of Northeast Pharmaceutical have successively passed the quality audits of 12 important domestic and foreign customers
.
From the perspective of intensive customer quality audits, it fully reflects the current increase in marketing needs of the company
.
It is understood that as an important domestic pharmaceutical production and export base, Northeast Pharmaceutical has been accelerating the optimization of the existing product sales structure, actively promoting the integration of related product business segments, and providing customers with solutions to closely connect sales and the market.
The company's raw materials are truly market-oriented
.
At present, Northeast Pharmaceutical is still actively exploring the international API market, accelerating the registration projects of Asia, Europe and South America and other regions and products, and enhancing the core competitiveness of the company.
It is expected that this will also lay a solid foundation for the export and sales of APIs in 2022.

.
In addition, Proton also announced on November 30 that the company has received a new batch of "Purchase Orders" from a large US pharmaceutical company.
The order is a CDMO order related to a small molecule innovative drug from a customer, totaling the order.
The scale is about 217 million US dollars, more than 50% of the company's operating income last year
.
Regarding the information of the overseas customer, Proton stated that it is inconvenient to disclose customer and product-related information according to the relevant agreement signed by the company and the customer due to the customer's trade secrets
.
However, it also revealed that the counterparty is a large pharmaceutical company in the United States with good credit and good performance capabilities
.
In general, China is one of the world's major API producers and exporters, and its export scale is gradually expanding
.
Affected by this, the export value of the entire API industry is also increasing steadily, and the export performance of related companies is also rising accordingly
.
However, it should be noted that the vast majority of API manufacturers in China are mostly private enterprises.
These companies are not only small in scale, but also weak in research and development capabilities.
They are mainly engaged in the production of bulk APIs, and the investment in technology R&D and innovation is generally insufficient
.
Therefore, in the context of the continuous development of China’s API industry, domestic API companies should also seize this opportunity to actively explore the API market in other countries, promote the accelerated upgrading and transformation of the domestic API industry, and better meet overseas requirements.
Customer needs
.